Skip to Main Content

Paper Details

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
Blood
24
2023
Author NameAffiliation
Felicitas Thol
Courtney D DiNardoThe University of Texas MD Anderson Cancer Center
  • 1 - 2

Datasets

Release 1.2